KBI-BIOPHARMA
6.7.2022 13:47:10 CEST | Business Wire | Press release
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Toluna Announces Planned CEO Transition After 25 Years; Founder Frédéric Charles Petit to remain as Board Member, Senior Advisor and Shareholder8.10.2026 16:20:00 CEST | Press release
Toluna, a global leader in consumer insights and market research technology, today announces a planned leadership transition. After 25 years leading the company he founded, Frédéric Charles Petit, Founder and Chief Executive Officer, intends to transition from his role as CEO following the appointment of his successor as part of a carefully planned succession process designed to ensure continuity for clients, employees and partners. Following the transition, Mr. Petit will continue to serve on Toluna's Board of Directors, will remain a significant shareholder of the company, and will take on an ongoing strategic advisory role for areas central to Toluna's next phase of growth. The Board, in close consultation with Mr. Petit, has initiated a structured succession process. A comprehensive transition plan is in place, including a defined handover with Mr. Petit, to ensure continuity for the company’s clients, employees, and partners. The Board expects to confirm the appointment of the com
CSC Wins for Threat Intelligence Innovation in 2026 CyberSecurity Breakthrough Awards8.10.2026 16:00:00 CEST | Press release
3D Domain Security and Global Enforcement recognized for excellence in an information security product CSC, an enterprise-class domain registrar and world leader in detecting and mitigating brand, fraud, domain, and Domain Name System (DNS) threat vectors, today announced that its 3D Domain Security and Global Enforcement solution won for Threat Intelligence Innovation in the 10th annual CyberSecurity Breakthrough Awards. The awards recognize the most innovative companies, products, and technologies driving progress in the global information security industry. CSC’s 3D Domain Security and Global Enforcement solution for the enterprise domain ecosystem combines advanced AI machine learning technology, proprietary domain threat intelligence, expert analysis, and integrated global enforcement. With this technology, organizations can detect, understand, and act on external cyber threats targeting their brand online across social media, search engines, email, and e-commerce websites. By unc
Stonebranch Launches Hybrid Orchestration Control Plane to Provide Governed Reliability in the Agentic Era8.10.2026 15:00:00 CEST | Press release
New capability in Universal Automation Center 8.1 connects automation, AI workflows, autonomous agents, and human approvals in a single governed process. Stonebranch, a leading provider of service orchestration and automation solutions, today announced the Hybrid Orchestration Control Plane, a new solution powered by Stonebranch Universal Automation Center™ (UAC) version 8.1. It lets enterprises run traditional automation, AI tasks, autonomous agents, and human decisions as one end-to-end workflow, with consistent permissions, approvals, service levels, audit trails, and recovery controls. Agents are spreading across the enterprise, but they act without the operational context around each decision: prior approvals, downstream dependencies, and recovery. Alone, they become another disconnected execution environment, with separate controls, fragmented visibility, and custom plumbing. The Hybrid Orchestration Control Plane connects them to existing automation in one governed process: agen
INNIO and Aggreko Extend Strategic Partnership Through 2031, Securing Long-Term Engine Capacity to Meet Growing Global Power Demand8.10.2026 14:37:00 CEST | Press release
INNIO N.V. (Nasdaq: INIO) today announced a substantial extension of its long-standing strategic partnership with Aggreko, a global leader in engineered energy and temperature solutions. The extended agreement, now running through 2031, secures substantial long-term engine capacity for Aggreko while providing INNIO with additional order visibility for medium-power range engines. “Global power demand is rising rapidly, while grid constraints are growing. Together with Aggreko, we are delivering reliable, efficient, and sustainable power solutions that help bridge these gaps and keep customers moving,” said Dr. Olaf Berlien, President and CEO of INNIO. “This agreement secures proven technology and capacity to deliver reliable power wherever and whenever our customers need it,” said Sunny Thakrar, Commercial Director of Aggreko. Under the agreement, INNIO has agreed to provide a minimum of 450 MW of engine capacity in the medium-power range (Jenbacher Type 4) in 2027 and access to agreed
Bacardi Climbs to #32 Among the World’s Top Companies for Women8.10.2026 14:11:00 CEST | Press release
Family-owned Bacardi is highest-ranked spirits company Bacardi Limited has climbed to #32 on the Forbes list of the World’s Top Companies for Women 2026, rising from #60 the previous year and earning a place on the prestigious global ranking for the fifth consecutive year. The family-owned company is the highest-ranked spirits company on this year’s list and ranks #2 in the “Food, Soft Beverages, Alcohol & Tobacco” category. The recognition reflects a continued commitment to creating opportunities, championing career development and cultivating a workplace where people feel valued, empowered and able to do their best work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008127263/en/ Bacardi celebrates being the highest-ranked spirits company in the Forbes World's Top Companies for Women 2026. “The most meaningful measure of our progress is seeing talented women choose to join Bacardi, build their careers here and advance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom